Alimena G - Search Results

1

Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy.

Breccia M, Molica M, Zacheo I, Alimena G. Breccia M, et al. Among authors: alimena g. Expert Opin Pharmacother. 2014 Aug;15(11):1621-30. doi: 10.1517/14656566.2014.936849. Epub 2014 Jul 3. Expert Opin Pharmacother. 2014. PMID: 24989987 Review.

2

Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. Expert Opin Drug Saf. 2010 Sep;9(5):713-21. doi: 10.1517/14740331003742935. Expert Opin Drug Saf. 2010. PMID: 20722490 Review.

3

NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. Expert Opin Ther Targets. 2010 Nov;14(11):1157-76. doi: 10.1517/14728222.2010.522570. Expert Opin Ther Targets. 2010. PMID: 20858024 Review.

4

5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.

Breccia M, Salaroli A, Loglisci G, Martelli M, D'Elia GM, Nanni M, Mauro FR, Alimena G. Breccia M, et al. Among authors: alimena g. Leuk Res. 2011 Oct;35(10):1409-11. doi: 10.1016/j.leukres.2011.05.030. Epub 2011 Jun 15. Leuk Res. 2011. PMID: 21680017

5

The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose.

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. Expert Opin Pharmacother. 2011 Sep;12(13):2075-87. doi: 10.1517/14656566.2011.597741. Epub 2011 Jul 1. Expert Opin Pharmacother. 2011. PMID: 21721847 Review.

6

5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.

Breccia M, Loglisci G, Salaroli A, Serrao A, Petrucci L, Mancini M, Alimena G. Breccia M, et al. Among authors: alimena g. Leuk Lymphoma. 2012 Aug;53(8):1558-60. doi: 10.3109/10428194.2012.660632. Epub 2012 Feb 21. Leuk Lymphoma. 2012. PMID: 22280532

7

Combination of azacitidine and ESA in myelodysplastic patients: the need for prospective studies.

Breccia M, Loglisci G, Salaroli A, Serrao A, Petrucci L, Zacheo I, Alimena G. Breccia M, et al. Among authors: alimena g. Leuk Res. 2012 Jun;36(6):682-3. doi: 10.1016/j.leukres.2012.02.020. Epub 2012 Mar 17. Leuk Res. 2012. PMID: 22424713 No abstract available.

8

Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.

Breccia M, Finsinger P, Loglisci G, Federico V, Santopietro M, Colafigli G, Petrucci L, Salaroli A, Serrao A, Latagliata R, Alimena G. Breccia M, et al. Among authors: alimena g. Ann Hematol. 2012 Sep;91(9):1345-9. doi: 10.1007/s00277-012-1481-7. Epub 2012 May 9. Ann Hematol. 2012. PMID: 22569854

9

Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far?

Breccia M, Voso MT, Alimena G. Breccia M, et al. Among authors: alimena g. Leuk Res. 2013 Feb;37(2):204-5. doi: 10.1016/j.leukres.2012.10.023. Epub 2012 Nov 20. Leuk Res. 2013. PMID: 23174191 No abstract available.

10

Efficacy and safety of deferasirox in myelodysplastic syndromes.

Breccia M, Alimena G. Breccia M, et al. Among authors: alimena g. Ann Hematol. 2013 Jul;92(7):863-70. doi: 10.1007/s00277-013-1703-7. Epub 2013 Feb 17. Ann Hematol. 2013. PMID: 23417759 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

361 results

Search Page

Filters